close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

88.20 -3.19 (-3.49%)
Streaming Delayed Price Updated: 12:58 PM EDT, Sep 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 290,552
Open 91.31
Bid (Size) 88.07 (100)
Ask (Size) 88.34 (100)
Prev. Close 91.39
Today's Range 88.12 - 91.50
52wk Range 63.23 - 130.00
Shares Outstanding 38,297,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
From Mirum Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+13.0%
+13.0%
1 Month
-8.8%
-8.8%
3 Month
-20.6%
-20.6%
6 Month
+0.4%
+0.4%
1 Year
+19.3%
+19.3%

More News

Read More
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat ↗
Via Chartmill
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗
Via MarketBeat
News headline image
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharma: A Rare Disease Growth Story to Watch ↗
Via MarketBeat
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?
Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.
What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?
Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?
The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market
What is the current price of Mirum Pharmaceuticals, Inc. - common stock?
The current price of Mirum Pharmaceuticals, Inc. - common stock is 88.20
When was Mirum Pharmaceuticals, Inc. - common stock last traded?
The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 09/23/26 12:58 PM ET
What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?
The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 3.38B
How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?
Mirum Pharmaceuticals, Inc. - common stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.